Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$201.99 USD

201.99
3,264,777

+8.81 (4.56%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

by Zacks Equity Research

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

What's in Store for Biogen (BIIB) This Earnings Season?

by Zacks Equity Research

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.

Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

by Zacks Equity Research

Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.

Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 19.57% and 6.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

by Zacks Equity Research

Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.

Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed the most recent trading day at $216.69, moving -0.65% from the previous trading session.

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

by Zacks Equity Research

Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

by Zacks Equity Research

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today

by Zacks Equity Research

Biogen Inc. (BIIB) reachead $219.40 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.

Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?

by Zacks Equity Research

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.

Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab

by Zacks Equity Research

The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $217.56 in the latest trading session, marking a +0.15% move from the prior day.

Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $217.23 in the latest trading session, marking a -1.71% move from the prior day.

Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market

by Zacks Equity Research

Biogen Inc. (BIIB) concluded the recent trading session at $221.74, signifying a -0.98% move from its prior day's close.

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research

Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.

Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

by Zacks Equity Research

Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.

Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease

by Zacks Equity Research

FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.

Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.

Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

by Zacks Equity Research

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.